ABUS | Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a hold rating in a report published on Monday, Zacks.com reports.According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection.The Company’s […]Stock Observer

ABUS | Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Zacks Investment Research

Arbutus Biopharma (NASDAQ:ABUS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports.According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection.[…] Dakota […]